Using dose-response characteristics of therapeutic agents for treatment decisions in type 2 diabetes

被引：14
作者：
Garber, AJ [1 ]
机构：
[1] Methodist Hosp, Baylor Coll Med, Houston, TX 77030 USA
来源：
DIABETES OBESITY & METABOLISM | 2000年 / 2卷 / 03期
关键词：
dose-response; metformin; sulphonylureas; troglitazone;
D O I：
10.1046/j.1463-1326.2000.00054.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：139 / 147
页数：9
相关论文
共 58 条
[1]  
*AM DIAB ASS, 1998, DIABETES CARE S1, V21, pS36
[2]  
American Diabetes Association, 1998, DIABETES CARE, pS23
[3]  
[Anonymous], 1995, Br. Med. J, DOI DOI 10.1136/BMJ.310.6972.83
[4]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI [10.1001/archinte.1997.00440420033005, DOI 10.1001/ARCHINTE.1997.00440420033005]
[5]   HYPOGLYCEMIC, ANTIHYPERGLYCEMIC AND ANTIDIABETIC DRUGS [J].
BAILEY, CJ .
DIABETIC MEDICINE, 1992, 9 (05) :482-483
[6]  
*BAY CORP, 1999, PREC AC TABL PACK IN
[7]   Insulin resistance: Current concepts [J].
Bloomgarden, ZT .
CLINICAL THERAPEUTICS, 1998, 20 (02) :216-231
[8]  
*BRIST MEY SQUIBB, 1998, GLUC METF HYDR PACK
[9]   Lactic acidosis rates in type 2 diabetes [J].
Brown, JB ;
Pedula, K ;
Barzilay, J ;
Herson, MK ;
Latare, P .
DIABETES CARE, 1998, 21 (10) :1659-1663
[10]  
CONIFF RF, 1994, ARCH INTERN MED, V154, P2442
123456